Cliff Asness's NTLA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 313,695 shares of Intellia Therapeutics, Inc. (NTLA) worth $2.82 M, representing 0.00% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in NTLA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 103,290 shares. Largest reduction occurred in Q2 2020, reducing 23,448 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +103,290 | Add 49.09% | 313,695 | $8.99 |
| Q3 2025 | +73,865 | Add 54.10% | 210,405 | $17.27 |
| Q2 2025 | +45,665 | Add 50.25% | 136,540 | $9.38 |
| Q1 2025 | +55,118 | Add 154.15% | 90,875 | $7.11 |
| Q4 2024 | +35,757 | New Buy | 35,757 | $11.66 |
| Q4 2022 | -5,048 | Sold Out | 0 | $0.00 |
| Q3 2022 | -3,230 | Reduce 39.02% | 5,048 | $55.86 |
| Q2 2022 | -17,707 | Reduce 68.14% | 8,278 | $51.70 |
| Q1 2022 | -14,715 | Reduce 36.15% | 25,985 | $72.66 |
| Q4 2021 | -6,777 | Reduce 14.27% | 40,700 | $118.23 |
| Q3 2021 | +11,901 | Add 33.45% | 47,477 | $134.15 |
| Q2 2021 | +3,872 | Add 12.21% | 35,576 | $161.91 |
| Q1 2021 | +11,414 | Add 56.25% | 31,704 | $80.24 |
| Q4 2020 | -5,454 | Reduce 21.19% | 20,290 | $54.41 |
| Q3 2020 | +5,169 | Add 25.12% | 25,744 | $19.89 |
| Q2 2020 | -23,448 | Reduce 53.26% | 20,575 | $21.00 |
| Q1 2020 | -15,614 | Reduce 26.18% | 44,023 | $12.22 |
| Q4 2019 | +23,099 | Add 63.22% | 59,637 | $14.67 |
| Q3 2019 | +36,538 | New Buy | 36,538 | $13.36 |
| Q4 2018 | -10,519 | Sold Out | 0 | $0.00 |
| Q3 2018 | +1,055 | Add 11.15% | 10,519 | $28.61 |
| Q2 2018 | -5,327 | Reduce 36.02% | 9,464 | $27.37 |
| Q1 2018 | +14,791 | New Buy | 14,791 | $21.09 |
| Q4 2017 | -22,640 | Sold Out | 0 | $0.00 |
| Q3 2017 | +10,137 | Add 81.08% | 22,640 | $24.87 |
| Q2 2017 | +12,503 | New Buy | 12,503 | $16.00 |
Cliff Asness's Intellia Therapeutics Investment FAQs
Cliff Asness first purchased Intellia Therapeutics, Inc. (NTLA) in Q2 2017, acquiring 12,503 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Intellia Therapeutics, Inc. (NTLA) for 26 quarters since Q2 2017.
Cliff Asness's largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q4 2025, adding 313,695 shares worth $2.82 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 313,695 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $2.82 M.
As of the Q4 2025 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Intellia Therapeutics, Inc. (NTLA) was 313,695 shares, as reported at the end of Q4 2025.